表紙
市場調査レポート

製薬・バイオテクノロジー・診断分野のロイヤルティファイナンシングに関する各種提携契約:契約条件・合意内容

Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 239652
出版日 ページ情報 英文 272 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
製薬・バイオテクノロジー・診断分野のロイヤルティファイナンシングに関する各種提携契約:契約条件・合意内容 Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016
出版日: 2016年05月02日 ページ情報: 英文 272 Pages
概要

当レポートでは、世界のバイオ医薬品事業者によるロイヤルティファイナンシング契約の動向について調査分析し、ロイヤルティファイナンシングの構造、メリット、契約動向、実際の契約のケーススタディ、大規模なロイヤルティファイナンシング契約、ロイヤルティファイナンシング契約を活発に行う事業者、契約文書、ディレクトリーなどをまとめています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 ロイヤルティファイナンシング契約に関する各種契約動向

  • イントロダクション
  • ロイヤルティファイナンシングとレベニューファイナンシングの違い
  • ロイヤルティファイナンシング契約の動向
  • ロイヤルティファイナンシング提携契約を締結する理由
  • ロイヤルティアセットの売買契約の台頭
    • ロイヤルティアセットの売買契約における主要企業
    • 最近のロイヤルティアセットの売買契約
    • ロイヤルティの買い戻しにおける大手医薬品事業者の役割
    • ロイヤルティアセットの売買契約の将来

第3章 ロイヤルティファイナンシングの構造:概要

  • イントロダクション
  • ロイヤルティアセットの売買契約の構造
  • ロイヤルティファイナンシング契約の例

第4章 主要契約

  • イントロダクション
  • 主要ロイヤルティファイナンシング契約:契約額別
  • 主要レベニューファイナンシング契約:契約額別
  • もっともアクティブなロイヤルティファイナンシングを行う事業者

第5章 ロイヤルティファイナンシング契約文書

  • イントロダクション
  • 企業A-Z

第6章 ロイヤルティファイナンシング契約ディレクトリー

  • イントロダクション
  • 企業A-Z
  • 治療分野別

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2061

The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understanding and analysis of how and why companies enter business, royalty financing agreements.

The focus of the report is on partnerships for royalty assets where partners have entered an agreement to dispose of or acquire said assets.

The report provides access to royalty financing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

  • Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
  • Revenue assets - also known as 'synthetic royalties', where a specialist investment company acquires the rights to a proportion of future revenue streams in return for a lump sum payment to the company

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report provides comprehensive access to royalty and revenue financing deals as announced in the life sciences industry since 2010.

This report contains links to online copies of actual royalty financing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of royalty financing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in royalty financing dealmaking as well as a discussion on the merits and attributes of royalty financing dealmaking.

Chapter 3 provides an overview of the structure of royalty financing deal contracts. The chapter includes numerous case studies to enable understanding of royalty financing deals for royalty assets.

Chapter 4 provides a review of the leading royalty financing deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive listing of royalty financing contract documents since 2010, including deal value, press release and contract document. The chapter is organized by company A-Z.

Chapter 6 provides a comprehensive listing of all royalty financing deal announcements and agreement contracts since 2010 available in the public domain. The chapter is organized by company A-Z and therapeutic area. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in royalty financing dealmaking.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty financing, enabling thorough learning, education and due diligence prior and during the royalty financing dealmaking process.

Key benefits

Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 provides the reader with the following key benefits:

  • In-depth understanding of royalty financing partnering deal trends since 2010
  • Analysis of the structure of royalty financing partnering agreements with numerous real life case studies
  • Comprehensive listing of all royalty financing deals since 2010, together with deal terms, value and press release
  • Comprehensive access to actual royalty financing partnering contracts entered into by the world's biopharma companies
  • Insight into the terms included in a royalty financing partnering agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 is intended to provide the reader with an in-depth understanding of the royalty financing trends and structure of deals entered into by leading biopharma companies worldwide.

Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 includes:

  • Trends in royalty financing dealmaking in the biopharma industry since 2010
  • Analysis of royalty financing deal structure
  • Case studies of real-life royalty financing deals
  • Comprehensive listing of royalty financing deals since 2010
  • Access to royalty financing contract documents
  • The leading royalty financing deals by value since 2010
  • Most active royalty financing dealmakers since 2010
  • The leading royalty financing partnering resources

In Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 report provides comprehensive access to available contract documents for royalty financing deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016 provides the reader with the following key benefits:

  • In-depth understanding of royalty financing partnering deal trends since 2010
  • Analysis of the structure of royalty financing partnering agreements with numerous real life case studies
  • Identify leading royalty financing deals by value since 2010
  • Identify the most active royalty financing dealmakers since 2010
  • Full listing of royalty financing deals by company A-Z and industry sector
  • Comprehensive access to over 60 royalty financing deals entered into by the world's biopharma companies, together with contract documents if available
  • Detailed access to actual royalty financing contracts entered into by the leading fifty big pharma and big biotech companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in royalty financing dealmaking

  • 2.1. Introduction
  • 2.2. Difference between royalty and revenue financing deals
  • 2.3. Trends in royalty financing deals since 2010
    • 2.3.1. Royalty financing dealmaking by year, 2010 to 2016
    • 2.3.2. Royalty financing dealmaking by industry sector, 2010 to 2016
    • 2.3.3. Royalty financing dealmaking by therapy area, 2010 to 2016
    • 2.3.4. Royalty financing dealmaking most active, 2010 to 2016
  • 2.4. Reasons for entering into royalty financing partnering deals
  • 2.5 The emergence of royalty asset purchase deals
    • 2.5.1. Primary players in royalty asset purchase deals
    • 2.5.2. Recent royalty asset purchase deals
    • 2.5.3. The role of big pharma in royalty buyback
    • 2.5.4. The future of royalty asset purchase deals

Chapter 3 - Overview of royalty financing structure

  • 3.1. Introduction
  • 3.2. Anatomy of a royalty asset purchase agreement
  • 3.3. Example royalty financing agreements
    • 3.3.1. Case study 1: Xoma - UCB - Orbimed Advisors
    • 3.3.2. Case study 2: Dyax - Paul Capital Healthcare
    • 3.3.3. Case study 3: Royalty financing: Biocryst Pharmaceuticals -Shionogi
    • 3.3.4. Case study 4: Royalty asset: TPG - CV Therapeutics

Chapter 4 - Leading royalty financing deals

  • 4.1. Introduction
  • 4.2. Top royalty financing deals by value

Chapter 5 - Top 10 most active royalty financing dealmakers

  • 5.1. Introduction
  • 5.2. Top 10 most active royalty financing dealmakers

Chapter 6 - Royalty financing contract documents 2010- 2016

Chapter 7 - Royalty financing agreement directory 2010- 2016

  • 7.1. Introduction
  • 7.2. Company A-Z
  • 7.3. By industry sector
  • 7.4. By therapy area

Appendices

  • Appendix 1 - Royalty financing references
  • Appendix 2 - Resources
  • Appendix 3 - Deal type definitions
  • Appendix 4 - Example royalty financing contract document

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

TABLE OF FIGURES

  • Figure 1: Definition of royalty assets
  • Figure 2: Trends in royalty financing deal announcements, 2010- 2016
  • Figure 3: Royalty financing deals signed by industry sector, 2010 to 2016
  • Figure 4: Royalty financing deals signed by therapy area, 2010 to 2016
  • Figure 5: Royalty financing deals moast active companies, 2010 to 2016
  • Figure 6: Leading royalty asset investors
  • Figure 7: Leading royalty asset purchase agreements by value, 2010- 2016
  • Figure 8: Components of the royalty asset purchase deal structure
  • Figure 9: Top royalty financing deals by value since 2010
  • Figure 10: Most active royalty financing dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Deal type definitions
  • Figure 13: Royalty financing agreement for Qutenza
Back to Top